Efficacy and Toxicity of Treatment of HL /Mature Data from a Single Centre
Richard Ward
Causes of Death and Excess Mortality after HL: the EORTC-GELA Experience
Olav Favier
Survival Patterns among HL Patients with a Family History of Lymphoma
Ola Landgren
10:30 – 12:00
Room: Großer Saal
Scientific SessionEarly Stage HL
Patrice Carde
David Straus
Defining the Role of Radiation Therapy (RT)
Richard Hoppe
Chemotherapy Only
Joseph Connors
Combined Modality Approaches
Andreas Engert
Results of the EORTC-GELA H9 Randomized Trials: the H9-F Trial (Comparing 3 Radiation Dose Levels) and H9-U Trial (Comparing 3 Chemotherapy Schemes) in Patients with Favorable or Unfavorable Early Stage HL
Jose Thomas
Stage I/II HL with Bulky Mediastinal Disease or other Risk Factors; The Stanford V Experience
Ranjana Advani
Chemotherapy is Essential for Optimal Treatment of Limited Stage Nodular Lymphocyte Predominant HL
Kerry J. Savage
12:15 – 13:45
Room: Großer Saal
Satellite Symposium
(by Sigma-Tau)
Procarbazine: An Established Drug with a New Life
Uwe Schlegel
Wolfgang Wick
Hodgkin Lymphoma: Better Cure with or without Procarbazine?
Volker Diehl
Therapy of primary CNS-Lymphomas: What’s new?
Uwe Schlegel
Molecular Predictors and Prognostic Markers in Brain Tumours.
Andreas von Deimling
What can we learn from Randomized Trials with Patients with Anaplastic Gliomas?
Wolfgang Wick
Investing in the Future of Cancer Patients
Alessandro Noseda
Summary and Closing Remarks
Volker Diehl
14:00 – 15:30
Room: Großer Saal
Scientific SessionRelapsed and Refractory Disease
Ralph Naumann
Norbert Schmitz
GHSG Trials in Relapsed HL
Peter Borchmann
The Role of Gemcitabine in the Treatment of Primary and Relapsed Disease
George Canellos
New Agents
Anas Younes
Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone (IGEV) and Fixed Dose of Lenograstim: an Effective Mobilization Regimen in Pretreated HL Patients
Massimo Magagnoli
A Phase II Study of MGCD0103, a Novel Oral Isotype-Selective Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory HL
Anas Younes
Promising Results for Patients with Relapsed or Refractory HL Treated with the Oral mTOR Inhibitor Everolimus (RAD001)
Patrick Johnston
16:00 – 17:30
Room: Großer Saal
Scientific SessionTranslational Research
Martin-Leo Hansmann
Ruth Jarrett
Biological Risk Factors for Stratification of HL Patients
Ruth Jarrett
The Role of the Microenvironment in HL
Randy Gascoyne
Analysing Differential Gene Expression and Genetic Lesions in HRS and L&H Cells to Identify New Therapeutic Targets
Ralf Küppers
Latent EBV Infection of HRS Cells Predicts Adverse Outcome in Older Adult Classical HL Patients
Arjan Diepstra
A Taqman-Low Density Array to Predict Outcome in HL Using Paraffin Embedded Samples
Beatriz Sanchez-Espiridion
Associations between Plasma Levels and Promoter Genotypes of IL-10 and IL-6 with Patient Characteristics and Outcome in HL
Stefan Hohaus
17:30 – 18:45
Room: Großer Saal
Main ProgramKey Note Lecture
The Role of Innate Immunity in Cancer Progression
Lisa Coussens
19:00 – 20:00
Room: Großer Saal
Satellite Symposium
(by Chugai Pharma)
Therapy of HL: Efficacy and Long Term Safety
Sandra Horning
Glycosylated G-CSF Mobilises More Clonogenic Progentiors than Non-Glycosylated G-CSF
Mike Watts
Treatment Associated Long Term Toxicity in HL Patients